How Much Savings Mabthera's and Herceptin's Biosimilars Generated in France?
Author(s)
Chassagnol F1, Chamielec C2, Tehard B3
1Roche SAS France, Boulogne-Billancourt Cedex, France, 2Dauphine university, PARIS, France, 3Roche, Boulogne-Billancourt, France
OBJECTIVES: Biosimilars reimbursment’s main objective is to generate savings through fast and significant price cuts. Biosimilars of MabThera (rituximab) and Herceptin (trastuzumab) were made available in France since August 2017 and July 2018 respectively, leading to an automatic 30% list price’s decrease of their IV form and a rapid and significant market share decrease. We estimated the savings generated by the reimbursement of rituximab IV and trastuzumab IV biosimilars in France METHODS: We conducted a retroactive budget impact analysis comparing the real combined revenue of rituximab and trastuzumab since 2017 January 1st and 2018 January 1st, respectively, until 2019 december 31st to a scenario where biosimilars would not have enter the French market. All market shares were extracted from the GERS hospital. Subcutaneous market share was maintained to its level just before biosimilars’ reimbursement and no price cut for MabThera and Herceptin were hypothesized in the alternative scenario RESULTS: Until 2019 december 31st, biosimilars allowed to generate €167 million (€127 million for rituximab and €40 million for trastuzumab). As Herceptin biosimilars’ reimbursement is recent, savings should continue increasing in the next years. CONCLUSIONS: Biosimilars’ access succeeded in generating important savings that should be dedicated to innovation funding
Conference/Value in Health Info
2020-11, ISPOR Europe 2020, Milan, Italy
Value in Health, Volume 23, Issue S2 (December 2020)
Code
PNS29
Topic
Economic Evaluation, Health Policy & Regulatory
Topic Subcategory
Budget Impact Analysis, Insurance Systems & National Health Care, Public Spending & National Health Expenditures, Reimbursement & Access Policy
Disease
No Specific Disease